VIRGINIA LAW PORTAL

• Code of Virginia
• Virginia Administrative Code
• Constitution of Virginia
• Charters
• Authorities
• Compacts
• Uncodified Acts
• RIS Users (account required)

SEARCHABLE DATABASES

• Bills & Resolutions
  session legislation
• Bill Summaries
  session summaries
• Reports to the General Assembly
  House and Senate documents
• Legislative Liaisons
  State agency contacts

ACROSS SESSIONS

• Subject Index: Since 1995
• Bills & Resolutions: Since 1994
• Summaries: Since 1994

Developed and maintained by the Division of Legislative Automated Systems.

2002 SESSION

• history | hilite | pdf | print version

CHAPTER 440 An Act to amend and reenact § 32.1-65 of the Code of Virginia, relating to newborn testing for medium-chain acyl-CoA dehydrogenase (MCAD or MCADH) deficiency. [S 218] Approved April 2, 2002

Be it enacted by the General Assembly of Virginia:

1. That § 32.1-65 of the Code of Virginia is amended and reenacted as follows:

§ 32.1-65. Infants to be subjected to tests.

In order to prevent mental retardation, permanent disability or death, every infant who is born in this Commonwealth shall be subjected to a screening test for biotinidase deficiency, phenylketonuria, hypothyroidism, homocystinuria, galactosemia, congenital adrenal hyperplasia, medium-chain acyl-CoA dehydrogenase (MCAD or MCADH) deficiency, and Maple Syrup Urine Disease, and each infant determined at risk shall be subject to a screening test for sickle cell diseases. Any infant whose parent or guardian objects thereto on the grounds that such test conflicts with his religious practices or tenets shall not be required to receive a screening test. The physician, nurse or midwife in charge of the delivery of a baby or, if none, the first attending physician shall cause such test to be performed. The screening tests shall be performed by the Division of Consolidated Laboratory Services or any other laboratory the Department of Health has contracted with to provide this service.

The program for screening infants for sickle cell diseases shall be conducted in addition to the programs provided for in Article 8 (§ 32.1-68 et seq.) of this chapter.

2. That the provisions of this act shall only become effective one year after the date that sufficient funds are appropriated or otherwise secured to (i) support the Virginia Department of Health’s costs for start-up professional and family education and (ii) the purchase of the necessary equipment for implementation of the testing program in the Division of Consolidated Laboratories.